Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

Phase 2

Terminated

• Conditions: Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)
• Interventions: Drug: TQB2450

• Registration Number: NCT04002622
• Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Brief Summary

TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-06-27
• Study First Submitted QC: 2019-06-27
• Study First Posted: 2019-06-28
• Study Start: 2019-08-06
• Status Verified: 2021-01
• Primary Completion: 2021-01-21
• Study Completion: 2021-01-21
• Last Update Submitted: 2021-01-21
• Last Update Posted: 2021-01-25

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

• 1. Histologically confirmed relapsed or refractory primary mediastinal large B-cell lymphoma.

  2. 18 and 75 years; Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; Life expectancy > 3 months.

  3. At least one measurable lesion. 4. Left ventricular ejection fraction (LVEF) measured by the cardiac echocardiography ≥ 50%.

  4. Screening laboratory values must meet the following criteria:hemoglobin ≥ 80 g/L; neutrophils ≥ 1.5*10^9/L; platelets ≥ 100 x 10^9/ L.

  5. Understood and signed an informed consent form.

Exclusion Criteria

• 1. Hypersensitivity to recombinant humanized anti-PD-1 monoclonal Abm or its components.

  2. Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody ,or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.

  3. Has received chemotherapy, surgery, radiotherapy, the last treatment from the first dose less than 4 weeks, or oral targeted drugs for less than 5 half-lives, or oral fluorouracil pyridine drugs for less than 14 days, mitomycin C and nitrosourea for less than 6 weeks.

  4. Has received emergency cytoreductive surgery to control tumors. 5. Has received allogeneic hematopoietic stem cell transplantation within the last 5 years.

  5. Has adverse events caused by previous therapy except alopecia that did not recover to ≤grade 1.

  6. Has diagnosed and/or treated additional malignancy within 5 years prior to randomization. Exceptions include basal cell skin cancer, squamous cell carcinoma of skin, melanoma skin and cancer carcinoma in situ of the cervix.

  7. Has definite central nervous system (CNS) infiltration of lymphoma, including brain parenchyma, meningeal invasion or spinal cord compression.

  8. Has any active autoimmune disease or a history of autoimmune disease. 10. Has serious or uncontrolled diseases such as history of chronic heart failure.

  9. Has any active autoimmune disease or a history of autoimmune disease. 12. Has received blood transfusion, erythropoietin granulocyte colony stimulating factor(G -CSF)，or Granulocyte macrophage colony stimulating factor(GM-CSF) within 4 weeks before the first dose.

  10. Has vaccinated with vaccines or attenuated vaccines within 4 weeks before the first dose.

  11. Has received surgery, or unhealed wounds within 4 weeks before the first dose.

  12. Has Hepatic, renal, blood coagulation dysfunction. 16. Has interstitial lung disease or non-infectious pneumonia and present residual lesions.

  13. Has received systemic treatment for active infection before the first dose.

  14. Has active or latent tuberculosis. 19. Hepatitis B virus surface antigen (HBsAg) positive, and hepatitis B virus DNA copy number > upper limit of normal.

  15. Human immunodeficiency virus antibody positive , hepatitis C antibody (HCV-Ab) and hepatitis C virus DNA copy number > upper limit of normal.

  16. Breastfeeding or pregnant women. 22. According to the judgement of the researchers, there are other factors that subjects are not suitable for the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
TQB2450	TQB2450	TQB2450 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle.

Primary Outcome Measures

Name	Time	Method
Objective Response Rate (ORR)	up to 96 weeks	Percentage of subjects achieving complete response (CR) and partial response (PR).

Secondary Outcome Measures

Name	Time	Method
Disease Control Rate (DCR)	up to 24 months	Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD).
Progression-Free Survival (PFS)	up to 96 weeks	PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.
Duration of Response (DOR)	up to 96 weeks	DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment.
Time to Response (TTR)	up to 24 months	TTR defined as time from the first dose to the first assessment of PR or CR.
Overall Survival (OS)	up to 24 months	OS defined as the time from randomization to death from any cause. Subjects who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.

Trial Locations

Locations (18)

First Hospital of Jilin University; 🇨🇳 Changchun, Jilin, China

Peking University Third Hospital; 🇨🇳 Beijin, Beijing, China

Shanghai Tongji Hospital; 🇨🇳 Shanghai, Shanghai, China

Qilu Hospital of Shandong University; 🇨🇳 Jinan, Shandong, China

Zhejiang Tumor Hospital; 🇨🇳 Hangzhou, Zhejiang, China

Peking Hospital; 🇨🇳 Beijin, Beijing, China

Union Medical College Hospital Affiliated to Fujian Medical University; 🇨🇳 Fuzhou, Fujian, China

Fifth Medical Center of the Chinese People's Liberation Army General Hospital; 🇨🇳 Beijing, Beijing, China

Peking Union Medical College Hospital; 🇨🇳 Beijing, Beijing, China

Henan Cancer Hospital; 🇨🇳 Zhengzhou, Henan, China

Sun Yat-sen University Cancer Center; 🇨🇳 Guangzhou, Guangdong, China

Cancer Hospital Affiliated to Harbin Medical University; 🇨🇳 Ha'erbin, Heilongjiang, China

Henan People's Hospital; 🇨🇳 Zhengzhou, Henan, China

Hunan Canser Hospital; 🇨🇳 Changsha, Hunan, China

First Affiliated Hospital of China Medical University; 🇨🇳 Shenyang, Liaoning, China

Affiliated Hospital of Qingdao University; 🇨🇳 Qingdao, Shandong, China

Shanghai Tumor Hospital; 🇨🇳 Shanghai, Shanghai, China

Peking University First Hospital; 🇨🇳 Beijing, Beijing, China